Wikidata

(Q63578322)

English

A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)

clinical trial

In more languages

Statements

short name
SLE-BRAVE-X (English)
0 references
title
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE) (English)
0 references
country
Argentina
0 references
Australia
0 references
Austria
0 references
Belgium
0 references
Brazil
0 references
Chile
0 references
Colombia
0 references
France
0 references
Germany
0 references
Hungary
0 references
India
0 references
Italy
0 references
Japan
0 references
Mexico
0 references
Netherlands
0 references
Philippines
0 references
Poland
0 references
Romania
0 references
Serbia
0 references
South Africa
0 references
Spain
0 references
Switzerland
0 references
Taiwan
0 references
United Kingdom
0 references
start time
30 August 2019
0 references
end time
1 February 2024
0 references
number of participants
1,100
0 references
research site
University of Michigan
0 references
University at Buffalo
0 references
University of Arizona
0 references
Piedmont HealthCare
0 references
Swedish Medical Center
0 references
Froedtert Hospital
0 references
Monash University
0 references
Griffith University
0 references
Tsinghua University
0 references
Rabin Medical Center
0 references
Hokkaido University
0 references
Tohoku University
0 references
Keio University
0 references
Asan Medical Center
0 references
University of Pretoria
0 references
Ohio State University
0 references
Emory University
0 references
Sun Yat-sen University
0 references
Peking University
0 references
Tel Aviv University
0 references
Juntendo University
0 references
Makati Medical Center
0 references
minimum age
18 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q63578322&oldid=1951105584"